New primary malignancy masquerading as metastatic prostate adenocarcinoma

Area of Science:

• Oncology
• Radiology
• Medical Diagnostics

Background:

• Prostate cancer management relies on radiographic findings to assess disease progression.
• New imaging findings can be misinterpreted as prostate cancer progression, leading to unnecessary treatment changes.
• Elevated prostate-specific antigen (PSA) levels typically support progression, but other factors must be considered.

Purpose of the Study:

• To highlight the diagnostic challenge posed by new radiographic findings mimicking prostate cancer progression.
• To present cases where new imaging findings represented a separate primary malignancy.
• To emphasize the importance of considering alternative diagnoses in specific clinical scenarios.

Main Methods:

• Retrospective case review of three patients with prostate adenocarcinoma.
• Analysis of radiographic findings (lymphadenopathy, bone lesions) and clinical data (PSA levels, symptoms).
• Histopathological confirmation of new primary malignancies.

Main Results:

• Three patients initially suspected of prostate cancer progression based on imaging.
• All three patients were ultimately diagnosed with a new, distinct primary malignancy.
• Stable PSA levels were a key factor in questioning prostate cancer progression.

Conclusions:

• New lymphadenopathy or bone lesions in prostate cancer patients should not automatically be attributed to disease progression.
• Stable PSA levels in the presence of suspicious imaging findings necessitate investigation for other malignancies.
• Careful evaluation considering all clinical parameters is crucial to avoid misdiagnosis and inappropriate treatment escalation.